300723 Stock Overview
ApicHope Pharmaceutical Co., Ltd, together with its subsidiaries, engages in the research and development, production, and sale of pharmaceutical drugs.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
ApicHope Pharmaceutical Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥21.36 |
| 52 Week High | CN¥34.34 |
| 52 Week Low | CN¥17.50 |
| Beta | 0.43 |
| 1 Month Change | -23.55% |
| 3 Month Change | -21.59% |
| 1 Year Change | -27.97% |
| 3 Year Change | 13.33% |
| 5 Year Change | 27.45% |
| Change since IPO | 134.92% |
Recent News & Updates
ApicHope Pharmaceutical (SZSE:300723) Has A Pretty Healthy Balance Sheet
Mar 15
Market Participants Recognise ApicHope Pharmaceutical Co., Ltd's (SZSE:300723) Earnings
Feb 27Shareholder Returns
| 300723 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -8.3% | -0.7% | -0.2% |
| 1Y | -28.0% | -15.9% | -17.8% |
Return vs Industry: 300723 underperformed the CN Pharmaceuticals industry which returned -15.9% over the past year.
Return vs Market: 300723 underperformed the CN Market which returned -17.8% over the past year.
Price Volatility
| 300723 volatility | |
|---|---|
| 300723 Average Weekly Movement | 8.5% |
| Pharmaceuticals Industry Average Movement | 7.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.4% |
Stable Share Price: 300723's share price has been volatile over the past 3 months.
Volatility Over Time: 300723's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 1,386 | Hanxiong Li | www.apichope.com |
ApicHope Pharmaceutical Co., Ltd, together with its subsidiaries, engages in the research and development, production, and sale of pharmaceutical drugs. Its pediatric medicines include fuganlin and yiqi jianpi oral liquid, carboxymestrine oral solution, and xiaoer kechuanling oral liquid products; and clindamycin hydrochloride palmitate dispersible tablet, acetylguitaricin dry suspension, qinxiangqingjie oral liquid, levocetirizine hydrochloride drop, epstein hydrochloride granule, clindamycin hydrochloride palmitate granule, clindamycin hydrochloride for injection, clindamycin phosphate injection, ambroxol hydrochloride drop, montelukast sodium granule, acyclovir for injection, and oseltamivir phosphate capsule products. The company’s chronic disease drugs comprise hepatocyte growth stimulating hormone and pentoxifylline for injections, kangshen granules, uqingshu granules, shenbai lotion products, compound monoammonium glycyrrhizinate S and lansoprazole for injections, houttuynia sodium tablets, omeprazole sodium and bromhexine hydrochloride for injections, huixinkang tablets, amlodipine benzenesulfonate dispersible tablets, yanhunin and sodium ferulate for injections, cyclic adenosine phosphate and ambroxol hydrochloride for injections, valsartan amlodipine tablets, and nifedipine controlled release tablets, as well as tricorutin, aceglutamide, vinpocetine, and doxofylline for injections.
ApicHope Pharmaceutical Co., Ltd Fundamentals Summary
| 300723 fundamental statistics | |
|---|---|
| Market cap | CN¥9.85b |
| Earnings (TTM) | CN¥306.67m |
| Revenue (TTM) | CN¥2.52b |
31.3x
P/E Ratio3.8x
P/S RatioIs 300723 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300723 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.52b |
| Cost of Revenue | CN¥443.83m |
| Gross Profit | CN¥2.07b |
| Other Expenses | CN¥1.76b |
| Earnings | CN¥306.67m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Apr 27, 2024
| Earnings per share (EPS) | 0.68 |
| Gross Margin | 82.35% |
| Net Profit Margin | 12.19% |
| Debt/Equity Ratio | 39.2% |
How did 300723 perform over the long term?
See historical performance and comparison